about
Role of Protein Aggregation in Mitochondrial Dysfunction and Neurodegeneration in Alzheimer's and Parkinson's DiseasesA blood-brain barrier (BBB) disrupter is also a potent α-synuclein (α-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD)Role of neurotrophic factor alterations in the neurodegenerative process in HIV associated neurocognitive disordersNeuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model.Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's diseaseS-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson's diseasealpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson diseaseAntidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophyPeptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's diseaseThe autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice.Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body diseaseGlucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.Chronic administration of the neurotrophic agent cerebrolysin ameliorates the behavioral and morphological changes induced by neonatal ventral hippocampus lesion in a rat model of schizophreniaA β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brainTime course and progression of wild type α-synuclein accumulation in a transgenic mouse model.Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo.The HIV Protein gp120 Alters Mitochondrial Dynamics in Neurons.Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides.Patterns of gene dysregulation in the frontal cortex of patients with HIV encephalitis.Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic miceIn vivo imaging of alpha-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility.Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseasesSelective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathyNeuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's diseaseWidespread microRNA dysregulation in multiple system atrophy - disease-related alteration in miR-96.Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.APP transgenic modeling of Alzheimer's disease: mechanisms of neurodegeneration and aberrant neurogenesisType 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice.α-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophyReducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophyMutant alpha-synuclein exacerbates age-related decrease of neurogenesis.Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors.Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure.Disease-Modifying Effect of Adiponectin in Model of α-Synucleinopathiesalpha-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells.Polyamine pathway contributes to the pathogenesis of Parkinson disease.Differential effects of UCHL1 modulation on alpha-synuclein in PD-like models of alpha-synucleinopathy.
P50
Q22241397-C6BD1851-8015-4FEB-9111-7EC5496128C7Q24612655-02FF47BC-DBBA-4247-9A8F-529E297D8622Q27025573-B96FC323-8D9C-4413-B4E5-D7E3BC3D0DC3Q27316651-25DED68A-ACB4-4C71-BB95-D96750024C7EQ27437619-02AB8FAF-50C2-46AE-A546-77587BECDED9Q28116512-88635E45-85EE-4225-8440-5D6C9F96D724Q28264682-9B88B506-827F-41C7-9144-BB655CD4B42CQ28395248-E19BF463-59CA-4C83-9DDE-96665B4461B8Q28546835-A89462F1-5E03-4617-97E7-9E9CC7C8C035Q28591283-54693826-1877-42CF-B35D-ABAA5C11EE99Q28740551-7F4A552A-A533-40E1-AC6B-B28801917A21Q30367337-840670E1-F08E-491A-B282-E60BFE70CA37Q30466753-1B38E0AF-D216-4FF3-B541-A3858DE55C80Q30498862-C6D87798-7CF9-4725-8443-B71FA252DF74Q30532478-E6380CAF-4D48-464C-86E6-69D905775DA0Q30578913-DB01C80B-BA3E-427A-9F17-FCC0B6882CB0Q30650119-0CD50CFD-FD80-4A38-ADB5-8E9BBC6ED72CQ30738175-404013FF-2B6D-42E3-B9F9-3B948865A486Q30845414-CA3D5D11-375D-4355-8037-EB0C45645021Q33209552-5BF73415-1FF7-4E05-AB76-9A0F860F7995Q33366459-4044F587-8725-46D4-979E-BA22C48CFEF9Q33384861-894CE2A0-904F-42FE-A42E-44FEA224FEFDQ33582289-EDB26170-D985-409A-B735-53213075ABA6Q33613123-E24C6413-DDF0-4820-9522-42C5208B2C13Q33670282-A535854B-01C5-4A9E-83E3-5AE9D3E88DDCQ33726762-90A72A65-32A3-473D-9ECB-79D1855A8FA3Q33738316-C51F19E1-40AB-43C3-9F56-331C1E208173Q33754643-8A6D32CB-3D4D-4563-ADB5-5B8C388547C1Q33759956-6296B40D-307F-4AF1-BCB2-32A5665F1727Q33828868-2010F99D-98AB-42DD-BFD5-DA7AB9CA4FA9Q33864597-C5B44516-24FF-4791-B49C-34177513B42DQ33865366-13A83826-1E95-4592-9C04-CC377E20DACCQ33914242-A6C2D3E4-0E05-4CC2-80F2-C8F404FE882BQ33958241-81C6C99F-BD69-4E36-BF8B-255630AE5B32Q33958289-D0997B2A-9095-4D4E-8DD8-467EE4C40ECFQ34006701-E0F2140B-0068-4DB0-9C70-592B5EEC03D4Q34026035-AF103C7D-A5FB-4C72-9151-B5CBBD3F70C4Q34109337-BB3C2069-E932-4F74-9922-D522F62806B6Q34165462-8C9F2CB6-34FE-4F17-9C89-6BBED9CA2D2FQ34238665-3256C08A-9764-4358-9F75-CF4CDBC7FDAD
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Edward Rockenstein
@ast
Edward Rockenstein
@en
Edward Rockenstein
@es
Edward Rockenstein
@nl
Edward Rockenstein
@sl
type
label
Edward Rockenstein
@ast
Edward Rockenstein
@en
Edward Rockenstein
@es
Edward Rockenstein
@nl
Edward Rockenstein
@sl
prefLabel
Edward Rockenstein
@ast
Edward Rockenstein
@en
Edward Rockenstein
@es
Edward Rockenstein
@nl
Edward Rockenstein
@sl